In the primary and secondary tumorsphere formation assay, which measures the self-renewal capacity of the cells, AZD4547 inhibited both primary and secondary tumorsphere formation in a dose-dependent manner in the ErbB2-overexpressing breast cancer cell lines (Fig. 2b). Here, ERBB2 is linked to breast carcinoma.